Shanghai Securities News China Securities News (Reporter Qiu Dekun) On the evening of February 23, Xuerong Bio’s official WeChat account announced that the company is very optimistic about the specific efficacy of Hydrangea in anti-cancer and activating immunity. The Institute of Materia Medica and other scientific research institutions cooperated to study the medicinal value of Hydrangea, and established Shanghai Xuerong Biopharmaceutical Co., Ltd. (hereinafter referred to as “Xuerong Medicine”).
Recently, Xuerong Pharmaceutical has cooperated with Japanese companies, starting from Hydrangea functional food, to carry out production and sales, gradually Expand to the field of pharmaceuticals, maximize the value of edible fungi, and extend the edible fungi industry chain. Hydrangea, also known as hydrangea mushroom, hydrangea mushroom, cauliflower mushroom, and petal velvet, is a rare and precious edible fungus, belonging to the order of Non-Syringomycetes, the family Hydrangea, and the genus Hydrangea.
Xuerong Bio is a modern agricultural enterprise that produces edible fungi in a factory-like manner based on modern biotechnology. ), king oyster mushroom, shiitake mushroom, velvet mushroom and other fresh edible mushrooms.
At present, the company is the largest industrial production enterprise of edible fungi in China, with a daily production capacity of 1,245 tons of edible fungi, ranking first in the country.
As of the end of June 2021, Xuerong Biotechnology and its subsidiaries have a total of 74 patents, including 21 invention patents, 44 utility model patents, and 9 design patents. Wisdom bud data shows that Xuerong Bio focuses on edible fungi, culture medium, liquid strains, bioengineering, cultivation bottles, culture medium formulations and other technical fields, and patents with high market value include “calcium-rich edible fungi production methods and culture medium formulations” “Wait.